ARROWHEAD PHARMACEUTICALS, INC. Investing Cash Flow
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Investing Cash Flow of -$874.34 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $43.68M, a 69.10% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$894.28M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$23.74M, a 130.87% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $72.62M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$129.29M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$420.07M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$96.16M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$5.42M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | -$850.60M derived: sum of 2 quarters · filed 2026-08-04 | -$874.34M 10-Q · filed 2026-08-04 | -$801.72M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$894.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | -$918.02M 10-Q · filed 2026-05-07 | -$845.40M derived: sum of 3 quarters · filed 2026-05-07 | -$704.01M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$23.74M 10-Q · filed 2026-02-05 | $48.88M derived: sum of 2 quarters · filed 2026-02-05 | $190.27M derived: sum of 3 quarters · filed 2026-08-04 | -$229.95M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-09-30 | $72.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $214.01M derived: sum of 2 quarters · filed 2026-08-04 | -$206.20M derived: sum of 3 quarters · filed 2026-08-04 | -$129.29M 10-K · filed 2025-11-25 | ||||
| 2025-06-30 | $141.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | -$278.82M derived: sum of 2 quarters · filed 2026-08-04 | -$201.91M 10-Q · filed 2026-08-04 | -$424.84M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$420.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | -$343.30M 10-Q · filed 2026-05-07 | -$566.23M derived: sum of 3 quarters · filed 2026-05-07 | -$559.28M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $76.91M 10-Q · filed 2026-02-05 | -$146.01M derived: sum of 2 quarters · filed 2026-02-05 | -$139.06M derived: sum of 3 quarters · filed 2026-02-05 | -$408.00M derived: sum of 4 quarters · filed 2026-02-05 | ||||
| 2024-09-30 | -$222.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$215.97M derived: sum of 2 quarters · filed 2025-11-25 | -$484.91M derived: sum of 3 quarters · filed 2025-11-25 | -$420.07M 10-K · filed 2025-11-25 | ||||
| 2024-06-30 | $6.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | -$261.99M derived: sum of 2 quarters · filed 2025-08-07 | -$197.15M 10-Q · filed 2025-08-07 | -$166.64M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2024-03-31 | -$268.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | -$204.10M 10-Q · filed 2025-05-12 | -$173.59M derived: sum of 3 quarters · filed 2025-11-25 | -$183.49M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2023-12-31 | $64.84M 10-Q · filed 2025-02-10 | $95.35M derived: sum of 2 quarters · filed 2025-11-25 | $85.44M derived: sum of 3 quarters · filed 2025-11-25 | $49.38M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2023-09-30 | $30.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $20.60M derived: sum of 2 quarters · filed 2025-11-25 | -$15.46M derived: sum of 3 quarters · filed 2025-11-25 | -$96.16M 10-K · filed 2025-11-25 | ||||
| 2023-06-30 | -$9.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | -$45.97M derived: sum of 2 quarters · filed 2024-08-08 | -$126.66M 10-Q · filed 2024-08-08 | -$90.22M derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2023-03-31 | -$36.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | -$116.76M 10-Q · filed 2024-05-09 | -$80.31M derived: sum of 3 quarters · filed 2024-11-26 | -$19.04M derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-12-31 | -$80.69M 10-Q · filed 2024-02-06 | -$44.25M derived: sum of 2 quarters · filed 2024-11-26 | $17.03M derived: sum of 3 quarters · filed 2024-11-26 | -$52.73M derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-09-30 | $36.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $97.72M derived: sum of 2 quarters · filed 2024-11-26 | $27.97M derived: sum of 3 quarters · filed 2024-11-26 | -$5.42M 10-K · filed 2024-11-26 | ||||
| 2022-06-30 | $61.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | -$8.48M derived: sum of 2 quarters · filed 2023-08-07 | -$41.86M 10-Q · filed 2023-08-07 | -$160.11M derived: sum of 4 quarters · filed 2023-11-29 | ||||
| 2022-03-31 | -$69.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | -$103.14M 10-Q · filed 2023-05-02 | -$221.38M derived: sum of 3 quarters · filed 2023-11-29 | -$240.93M derived: sum of 4 quarters · filed 2023-11-29 | ||||
| 2021-12-31 | -$33.38M 10-Q · filed 2023-02-06 | -$151.63M derived: sum of 2 quarters · filed 2023-11-29 | -$171.17M derived: sum of 3 quarters · filed 2023-11-29 | -$205.22M derived: sum of 4 quarters · filed 2023-11-29 | ||||
| 2021-09-30 | -$118.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | -$137.79M derived: sum of 2 quarters · filed 2023-11-29 | -$171.84M derived: sum of 3 quarters · filed 2023-11-29 | -$141.68M 10-K · filed 2023-11-29 | ||||
| 2021-06-30 | -$19.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-04 | -$53.59M derived: sum of 2 quarters · filed 2022-08-04 | -$23.43M 10-Q · filed 2022-08-04 | -$89.33M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2021-03-31 | -$34.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-10 | -$3.89M 10-Q · filed 2022-05-10 | -$69.79M derived: sum of 3 quarters · filed 2022-11-28 | -$75.82M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2020-12-31 | $30.16M 10-Q · filed 2022-02-02 | -$35.74M derived: sum of 2 quarters · filed 2022-11-28 | -$41.77M derived: sum of 3 quarters · filed 2022-11-28 | -$219.90M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2020-09-30 | -$65.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | -$71.93M derived: sum of 2 quarters · filed 2022-11-28 | -$250.06M derived: sum of 3 quarters · filed 2022-11-28 | -$240.78M 10-K · filed 2022-11-28 | -$240.78M 10-K · filed 2020-11-23 | |||
| 2020-06-30 | -$6.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-05 | -$184.16M derived: sum of 2 quarters · filed 2021-08-05 | -$174.88M 10-Q · filed 2021-08-05 | -$174.88M 10-Q · filed 2020-08-05 | -$158.05M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2020-03-31 | -$178.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-04 | -$168.85M 10-Q · filed 2021-05-04 | -$168.85M 10-Q · filed 2020-05-07 | -$152.02M derived: sum of 3 quarters · filed 2021-11-22 | -$137.62M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2019-12-31 | $9.28M 10-Q · filed 2021-02-04 | $9.28M 10-Q · filed 2020-02-05 | $26.11M derived: sum of 2 quarters · filed 2021-11-22 | $40.51M derived: sum of 3 quarters · filed 2021-11-22 | $29.29M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2019-09-30 | $16.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22 | $31.23M derived: sum of 2 quarters · filed 2021-11-22 | $20.01M derived: sum of 3 quarters · filed 2021-11-22 | -$47.75M 10-K · filed 2021-11-22 | -$47.75M 10-K · filed 2019-11-25 | |||
| 2019-06-30 | $14.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | $3.18M derived: sum of 2 quarters · filed 2020-08-05 | -$64.58M 10-Q · filed 2020-08-05 | -$61.33M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2019-03-31 | -$11.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07 | -$78.97M 10-Q · filed 2020-05-07 | -$75.73M derived: sum of 3 quarters · filed 2020-11-23 | -$104.58M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2018-12-31 | -$67.76M 10-Q · filed 2020-02-05 | -$64.51M derived: sum of 2 quarters · filed 2020-11-23 | -$93.36M derived: sum of 3 quarters · filed 2020-11-23 | -$76.55M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2018-09-30 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-23 | -$25.61M derived: sum of 2 quarters · filed 2020-11-23 | -$8.79M derived: sum of 3 quarters · filed 2020-11-23 | -$7.43M 10-K · filed 2020-11-23 | ||||
| 2018-06-30 | -$28.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-05 | -$12.04M derived: sum of 2 quarters · filed 2019-08-05 | -$10.68M 10-Q · filed 2019-08-05 | -$14.90M derived: sum of 4 quarters · filed 2019-11-25 | ||||
| 2018-03-31 | $16.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-08 | $18.17M 10-Q · filed 2019-05-08 | $13.95M derived: sum of 3 quarters · filed 2019-11-25 | |||||
| 2017-12-31 | $1.36M 10-Q · filed 2019-02-07 | -$2.86M derived: sum of 2 quarters · filed 2019-11-25 | ||||||
| 2017-09-30 | -$4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | -$48.64M 10-K · filed 2019-11-25 | ||||||
| 2017-06-30 | -$44.43M 10-Q · filed 2018-08-07 | |||||||
| 2016-09-30 | $13.45M 10-K · filed 2018-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |